{"schema_version":"secwatch.filing_event.v1","accession":"0001601830-24-000165","form_type":"8-K","ticker":"RXRX","cik":"0001601830","company_name":"RECURSION PHARMACEUTICALS, INC.","filed_at":"2024-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.935792+00:00","generated_at":"2026-05-30T22:34:06.253438+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"FDA clears IND for Recursion's REC-1245, a first-in-class RBM39 degrader for solid tumors/lymphoma","bullets":["FDA cleared IND for REC-1245, a potential first-in-class RBM39 degrader for biomarker-enriched solid tumors and lymphoma.","Phase 1/2 trial to start Q4 2024 evaluating safety, tolerability, PK/PD, and monotherapy efficacy.","Target identified via Recursion's AI platform; program advanced from target to IND in under 18 months.","Initially addressable population estimated at >100,000 patients in the US and EU5.","Preclinical data show RBM39 degradation induces splicing defects downregulating DNA Damage Response networks."],"urls":{"canonical":"https://secwatch.observer/filing/0001601830-24-000165","json":"https://secwatch.observer/filing/0001601830-24-000165.json","markdown":"https://secwatch.observer/filing/0001601830-24-000165.md","text":"https://secwatch.observer/filing/0001601830-24-000165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000165/0001601830-24-000165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1601830/000160183024000165/rxrx-20241002.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T22:34:06.253438+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001193125-26-251421","ticker":"GENC","company_name":"GENCOR INDUSTRIES INC","filed_at":"2026-06-01T20:09:26+00:00","headline":"Gencor receives NYSE American delinquency notice for late Q2 2026 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251421","json":"https://secwatch.observer/filing/0001193125-26-251421.json","markdown":"https://secwatch.observer/filing/0001193125-26-251421.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/0001193125-26-251421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/64472/000119312526251421/d135716d8k.htm"},"side_by_side_evidence":null},{"accession":"0001140361-26-023560","ticker":"NJR","company_name":"NEW JERSEY RESOURCES CORP","filed_at":"2026-06-01T20:03:21+00:00","headline":"NJNG files base rate case seeking $157.6M increase; offers 8.9% winter bill cut","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023560","json":"https://secwatch.observer/filing/0001140361-26-023560.json","markdown":"https://secwatch.observer/filing/0001140361-26-023560.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/356309/000114036126023560/0001140361-26-023560-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/356309/000114036126023560/ef20075084_8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026519","ticker":"ELTP","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2026-06-01T11:00:24+00:00","headline":"Elite Pharmaceuticals files ANDA for generic anticoagulant; $26B brand market, no generic available","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026519","json":"https://secwatch.observer/filing/0001493152-26-026519.json","markdown":"https://secwatch.observer/filing/0001493152-26-026519.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226026519/0001493152-26-026519-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226026519/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":null},{"accession":"0001628280-26-039005","ticker":"BDX","company_name":"BECTON DICKINSON & CO","filed_at":"2026-05-29T12:39:28+00:00","headline":"BD resumes ChloraPrep shipments after voluntary hold; all final release testing acceptable","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039005","json":"https://secwatch.observer/filing/0001628280-26-039005.json","markdown":"https://secwatch.observer/filing/0001628280-26-039005.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/10795/000162828026039005/0001628280-26-039005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/10795/000162828026039005/bdx-20260529.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-025629","ticker":"CDT","company_name":"CDT Equity Inc.","filed_at":"2026-05-28T20:30:30+00:00","headline":"CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025629","json":"https://secwatch.observer/filing/0001493152-26-025629.json","markdown":"https://secwatch.observer/filing/0001493152-26-025629.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/0001493152-26-025629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-067275","ticker":"TMC","company_name":"TMC the metals Co Inc.","filed_at":"2026-05-28T13:04:46+00:00","headline":"NOAA certifies TMC USA's exploration license for USA B; 1.02B tonne nodule resource","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-067275","json":"https://secwatch.observer/filing/0001104659-26-067275.json","markdown":"https://secwatch.observer/filing/0001104659-26-067275.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1798562/000110465926067275/0001104659-26-067275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1798562/000110465926067275/tm2615882d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001437749-26-018670","ticker":"BCDA","company_name":"BioCardia, Inc.","filed_at":"2026-05-28T12:00:11+00:00","headline":"BioCardia Japan PMDA supports CardiAMP cell therapy submission for HFrEF; submission planned Q4 2026","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-018670","json":"https://secwatch.observer/filing/0001437749-26-018670.json","markdown":"https://secwatch.observer/filing/0001437749-26-018670.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/925741/000143774926018670/0001437749-26-018670-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/925741/000143774926018670/bcda20260528_8k.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}